C. E. Cox

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Preparing the “Soil”: The Primary Tumor Induces Vasculature Reorganization in the Sentinel Lymph Node before the Arrival of Metastatic Cancer Cells

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

Triple-negative breast cancer molecular subtyping and treatment progress

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer

Estrogen Receptors: How Do They Signal and What Are Their Targets

Global cancer statistics

Historical perspective on hormonal therapy of advanced breast cancer

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions

Breast Cancer in Limited-Resource Countries: Health Care Systems and Public Policy

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry

Global Patterns of Cancer Incidence and Mortality Rates and Trends

Breast cancer metastasis: markers and models

Molecular Biology and Pathology of Lymphangiogenesis

Trends and Variation in Use of Breast Reconstruction in Patients With Breast Cancer Undergoing Mastectomy in the United States

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 Randomized Trial

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

Cancer treatment and survivorship statistics, 2014

A National Snapshot of Satisfaction with Breast Cancer Procedures

NCCN Practice Guidelines for Breast Cancer.